Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain

• Published in: Advanced drug delivery reviews Vol. 197; p. 114820
• Main Authors: Wu, Jason R., Hernandez, Yazmin, Miyasaki, Katelyn F., Kwon, Ester J.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2023
• Subjects: BBB dysfunction; Biological Transport; Blood-brain barrier; Blood-Brain Barrier - metabolism; Brain; Cancer; Cellular hitchhiking; Endothelial cells; Focused ultrasound; Humans; Nanomaterials; Nanostructures; Neurodegenerative disease; Neuroinflammation; Permeability; Physicochemical properties; Receptors; Stroke - metabolism; Tight junctions; Transcytosis; Traumatic brain injury; TfR; Traumatic brain injury; BBB; Cellular hitchhiking; CNS; mRNA; NVU; Receptors; RBC; GBM; Blood-brain barrier; ECs; Neurodegenerative disease; Transcytosis; Focused ultrasound; TBI; P-gp; Tight junctions; FUS; Nanomaterials; Neuroinflammation; AJ; Permeability; BBB dysfunction; Endothelial cells; NPs; PEG; TJ; RMT; ABC transporter; Physicochemical properties; Cancer
• ISSN: 0169-409X; 1872-8294
• DOI: 10.1016/j.addr.2023.114820

[Display omitted] The blood–brain barrier (BBB) is a highly regulated physical and functional boundarythat tightly controls the transport of materials between the blood and the brain. There is an increasing recognition that the BBB is dysfunctional in a wide range of neurological disorders; this dysfunction can be symptomatic of the disease but can also play a role in disease etiology. BBB dysfunction can be exploited for the delivery of therapeutic nanomaterials. Forexample, there can be a transient, physical disruption of the BBB in diseases such as brain injury and stroke, which allows temporary access of nanomaterials into the brain. Physicaldisruption of the BBB through external energy sources is now being clinically pursued toincrease therapeutic delivery into the brain. In other diseases, the BBB takes on new properties that can beleveraged by delivery carriers. For instance, neuroinflammation induces the expression ofreceptors on the BBB that can be targeted by ligand-modified nanomaterials, and theendogenous homing of immune cells into the diseased brain can be hijacked for the delivery ofnanomaterials. Lastly, BBB transport pathways can be altered to increase nanomaterial transport. In this review, we will describe changes that can occur in the BBB in disease, and how these changes have been exploited by engineered nanomaterials forincreased transport into the brain.